Progranulin expression in breast cancer with different intrinsic subtypes

Pathology Research and Practice

Volumn 208, Issue 4, 2012, Pages 210-216

  Li, Li Qin ^a   Min, Li Shan ^a   Jiang, Qun ^b   Ping, Jin Liang ^a   Li, Jing ^a   Dai, Li Cheng ^a  

^a HUZHOU UNIVERSITY   (China)

^b Nanxing Community Health Service Center   (China)

Author keywords

Angiogenesis; CD105; Progranulin; Triple negative breast cancer; VEGF

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROGRANULIN; PROTEIN P53; UVOMORULIN; VASCULOTROPIN;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST FIBROADENOMA; CANCER CLASSIFICATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FIBROADENOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPH NODES; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862778273     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.02.001     Document Type: Article

References (31)

1. Andre F., Dessen P., Job B., Delaloge S., Pusztai L., Lazar V. Functional pathways analyses to identify candidate therapeutic targets in triple-negative breast cancer. J. Clin. Oncol. 2009, 27:569.
2. Brenton J.D., Carey L.A., Ahmed A.A., Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J. Clin. Oncol. 2005, 23:7350-7360.
3. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., Karaca G., Troester M.A., Tse C.K., Edmiston S., Deming S.L., Geradts J., Cheang M.C., Nielsen T.O., Moorman P.G., Earp H.S., Millikan R.C. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006, 295:2492-2502.
4. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., Ollila D.W., Sartor C.I., Graham M.L., Perou C.M. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13:2329-2334.
5. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., Watson M., Davies S., Bernard P.S., Parker J.S., Perou C.M., Ellis M.J., Nielsen T.O. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer. Inst. 2009, 101:736-750.
6. Chen X.Y., Li J.S., Liang Q.P., He D.Z., Zhao J. Expression of PC cell-derived growth factor and vascular endothelial growth fact or in esophageal squamous cell carcinoma and their clinicopathologic significance. Chin. Med. J. 2008, 121:881-886.
7. Crabb S.J., Cheang M.C., Leung S., Immonen T., Nielsen T.O., Huntsman D.D., Bajdik C.D., Chia S.K. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin. Breast Cancer 2008, 8:249-256.
8. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., Narod S.A. Triple negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13:4429-4434.
9. Desmarais J.A., Cao M.J., Bateman A., Murphy B.D. Spatiotemporal expression pattern of progranuliln in embryo implantation and placenta formation suggests a role in cell proliferation, remodeling, and angiogenesis. Reproduction 2008, 136:247-257.
10. Fornier M., Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. Breast J. 2011, 10.1111/j.1524-4741.2011.01175.x.
11. Foulkes W.D, Grainge M.J., Rakha E.A., Green A.R., Ellis I.O. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res. Treat. 2009, 117:199-204.
12. Gluz O., Liedtke C., Gottschalk N., Pusztai L., Nitz U., Harbeck N. Triple-negative breast cancer-current status and future directions. Ann. Oncol. 2009, 20:1913-1927.
13. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann. Oncol. 2005, 16:1569-1583.
14. Greenberg S., Rugo H.S. Triple-negative breast cancer: role of antiangiogenic agents. Cancer J. 2010, 16:33-38.
15. Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., Harris L., Hait W., Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer. J. Clin. Oncol. 2006, 24:5652-5657.
16. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., Fitzgibbons P.L., Francis G., Goldstein N.S., Hayes M., Hicks D.G., Lester S., Love R., Mangu P.B., McShane L., Miller K., Osborne C.K., Paik S., Perlmutter J., Rhodes A., Sasano H., Schwartz J.N., Sweep F.C., Taube S., Torlakovic E.E., Valenstein P., Viale G., Visscher D., Wheeler T., Williams R.B., Wittliff J.L., Wolff A.C. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2010, 28:2784-2795.
17. He Z., Bateman A., Progranuliln (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J. Mol. Med. 2003, 81:600-602.
18. Hugh J., Hanson J., Cheang M.C., Nielsen T.O., Perou C.M., Dumontet C., Reed J., Krajewska M., Treilleux I., Rupin M., Magherini E., Mackey J., Martin M., Vogel C. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J. Clin. Oncol. 2009, 27:1168-1176.
19. Irshad S., Ellis P., Tutt A. Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Curr. Opin. Oncol. 2011, 23:566-577.
20. Li L.Q., Huang H.L., Ping J.L., Wang X.H., Zhong J., Dai L.C. Clinicopathological and prognostic implications of progranulin in breast carcinoma. Chin. Med. J. 2011, 124:2045-2050.
21. Lin N.U., Claus E., Sohl J., Razzak A.R., Arnaout A., Winer E.P. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008, 113:2638-2645.
22. Linderholm B.K., Hellborg H., Johansson U., Elmberger G., Skoog L., Lehtio J., Lewensohn R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann. Oncol. 2009, 20:1639-1646.
23. Lopes N., Sousa B., Vieira D., Milanezi F., Schmitt F. Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles. Histopathology 2009, 55:594-599.
24. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., Shenkier T., Cella D., Davidson N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357:2666-2676.
25. Perou C.M., Sorlie T., Eisen M.B., van de Rijin M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumors. Nature 2000, 406:747-752.
26. Reiss Y., Knedla A., Tal A.O., Schmidt M.H., Jugold M., Kiessling F., Burger A.M., Wolburg H., Deutsch U.K.H. Plate.Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2. J. Pathol. 2009, 217:571-580.
27. Rydén L., Jirström K., Haglund M., Stål O., Fernö M. Vascular endothelial growth factor receptor 2 is a significant negative prognostic biomarker in triple-negative breast cancer: results from a controlled randomised trial of premenopausal breast cancer. Cancer Res. 2009, 69:132S.
28. Tan A.R., Swain S.M. Therapeutic strategies for triple-negative breast cancer. Cancer J. 2008, 14:343-351.
29. Tangkeangsirisin W., Serrero G. PC cell-derived growth factor (Progranulin/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells. Carcinogenesis 2004, 25:1587-1592.
30. Trepp R., Padberg B.C., Varga Z., Cathomas R., Inauen R., Reinhart W.H. Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. Pathol. Res. Pract. 2010, 206:334-337.
31. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American society of clinical oncology/college of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.